Navigation Links
UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
Date:11/5/2013

SYDNEY, Nov. 5, 2013 /PRNewswire/ -- UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001, in two presentations at the 15th World Conference for Lung Cancer, in Sydney, from October 27-30. The multicenter, randomized Phase II clinical trial of DPV-001 is supported by a US$3.4 million National Cancer Institute (NCI) grant and will involve 48 individuals with definitively treated stage IIIA/B non-small cell lung cancer (NSCLC). A description of DPV-001, an "off-the-shelf vaccine," was presented by Dr. Helen Ross, Mayo Clinic Arizona, in an oral session (abstract #O-08.01). This next generation vaccine contains a system for targeting to dendritic cells, at least 9 cancer antigens prioritized by an NCI advisory panel and 5 toll-like receptor agonists to boost immunity. "Patients with locally advanced lung cancer still have a very high risk of cancer returning despite our most aggressive treatments," said Dr. Rachel Sanborn, the trial's principal investigator and the Co-Director of Thoracic Oncology, Providence Cancer Center, Portland, Oregon. "This novel vaccine approach may help the immune system recognize and fight remaining cancer cells." In a presentation of the Phase 1 trial in patients with Stage IV NSCLC, the authors reported that immune responses were detected in a majority of the evaluable patients (abstract # P-3.11-032).

"UbiVac is excited to pioneer this first-in-class vaccine technology to patients with NSCLC," said Dr. Hong-Ming Hu, inventor of autophagosome DRibble technology, Co-founder and CSO of UbiVac. "In addition to lung cancer, UbiVac is actively pursuing the application of this technology, with our partners and collaborators, for the treatment of head and neck, hepatocellular, prostate, colon and breast cancer."

UbiVac, spun-out from the Providence Health System in 2005, recently was judged by Oregon CEOs as the top "Presenting Company" at the Oregon Bioscience Association annual meeting has three vaccine platform technologies under development: DRibbles, a nanotechnology platform and a disabled cytomegalovirus (CMV) vector platform.

The ongoing activities reported in this release are supported by the NCI of the National Institutes of Health under Award Numbers R44CA121612 and U43CA165048. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the National Institutes of Health.


'/>"/>
SOURCE UbiVac
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotest Opens New Plasma Center in Melbourne, Florida
2. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
3. AdvaMed 2013: The MedTech Conference Opens Monday in Washington, D.C.
4. Unique Glaucoma Test Through Eyelid DIATON Opens Doctors Eyes to Possibility of In-Office Glaucoma Test at Pri-Med East and American Academy of Family Physicians, AAFP
5. Dr. George O. Gavrila Opens Baltimore Tattoo Removal, Offers Astanza Duality Laser Technology
6. Boston Scientific Opens Institute For Advancing Science, Innovation Center In Shanghai
7. BioReliance Opens New U.S. Clearance Services Laboratories; Completes Global Facility Upgrade Plan
8. MinuteClinic Opens Its First Walk-in Medical Clinic in Southwest Virginia
9. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
10. Life Technologies Opens State-of-the-Art DNA Forensics Laboratory in India
11. MinuteClinic Opens Its First Medical Clinics in Lehigh Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017 Clarius Mobile Health, ... handheld ultrasound scanners this week at the American ... (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians to ... rate, and evaluate pregnancy-related complications like ectopic pregnancy ...
(Date:5/4/2017)... , May 4, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... or the "Company"), today announced that the Company,s first ... close on Thursday, May 11, 2017, and that the ... at 1:30 p.m. PT that afternoon. Management will provide ...
(Date:5/3/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: WST), ... drug administration, announced today that Fran DeGrazio ... and Diane Paskiet , Director, Scientific Affairs, ... on West,s expertise in the areas of safety ... providing commentary on updated industry guidance. ...
Breaking Medicine Technology:
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Yisrayl ... a new publication this week that is focusing on the Peace Agreements being discussed ... his Middle East sprint in a race to try to speed up peace talks ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based ... of proceeds from its 14th Annual Clays for Kids fundraiser, to be held ... Bennett, Colorado. , As part of BluSky’s partnership with The Adoption Exchange, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the ... Jersey School District had left education officials with a number of critical issues to ... the flooring had to be accomplished with little or no disruption to class schedules. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is ... York City. He is known for his distinguished expertise and experience in the diagnosis ... holds sub-specialty training in treating renovascular disease and aortic aneurysm . He is ...
Breaking Medicine News(10 mins):